文献速递组学、生物样本库与精准医学基础与转化研究医学人工智能与信息学

代谢功能障碍相关脂肪性肝病基因至结局多模态数据库

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Nat Med · 2023-10-30

研究建立940例经组织学定义、覆盖完整MASLD严重度谱系的回顾性全国队列,并创建可搜索开放资源SteatoSITE;

要点

  • 15基因转录风险评分预测肝脏失代偿,1年、3年、5年AUC分别为0.86、0.81、0.83。
  • 甲状腺激素受体β调节子活性被识别为疾病进展的关键抑制因素。

核心结论

  • SteatoSITE支持合理的生物标志物与药物开发,并促进MASLD患者的精准医学方法。

研究设计与样本

  • 建立940例经组织学定义的MASLD患者回顾性全国队列,覆盖完整MASLD严重度谱系,其中男性55.4%、女性44.6%,中位体重指数31.3,32%合并2型糖尿病。
  • 对668例病例和39例对照生成肝脏批量RNA测序数据,进行差异基因表达与通路分析,包括性别特异性差异探索,并开发基于网络的基因浏览器。

主要发现

  • 定义与不良结局相关的疾病阶段特异性基因表达特征、致病性肝细胞亚群和主调控网络。
  • 构建15基因转录风险评分预测未来肝脏失代偿事件,1年、3年、5年风险的受试者工作特征曲线下面积分别为0.86、0.81和0.83。
  • 甲状腺激素受体β调节子活性被识别为疾病进展的关键抑制因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet precision medicine challenge. We established a retrospective national cohort of 940 histologically defined patients (55.4% men, 44.6% women; median body mass index 31.3; 32% with type 2 diabetes) covering the complete MASLD severity spectrum, and created a secure, searchable, open resource (SteatoSITE). In 668 cases and 39 controls, we generated hepatic bulk RNA sequencing data and performed differential gene expression and pathway analysis, including exploration of gender-specific differences. A web-based gene browser was also developed. We integrated histopathological assessments, transcriptomic data and 5.67 million days of time-stamped longitudinal electronic health record data to define disease-stage-specific gene expression signatures, pathogenic hepatic cell subpopulations and master regulator networks associated with adverse outcomes in MASLD. We constructed a 15-gene transcriptional risk score to predict future hepatic decompensation events (area under the receiver operating characteristic curve 0.86, 0.81 and 0.83 for 1-, 3- and 5-year risk, respectively). Additionally, thyroid hormone receptor beta regulon activity was identified as a critical suppressor of disease progression. SteatoSITE supports rational biomarker and drug development and facilitates precision medicine approaches for patients with MASLD.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Kendall TJ, Jimenez-Ramos M, Turner F, et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2023. PMID: 37903863. doi:10.1038/s41591-023-02602-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。